The FDA on November 13, 2015 granted accelerated approval to TAGRISSO® once daily tablets, for the treatment of patients with metastatic Epidermal Growth Factor Receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR Tyrosine Kinase Inhibitor (TKI) therapy. TAGRISSO® is a product of AstraZeneca Pharmaceuticals LP.
Other Pages – Bottom Ad
Advertisement
Subscribe
